Our story

Equity-based access with Fintech solution

MedScore aims to enable equity-based access to quality drugs and treatment, starting with providing patient household credit scoring and market-access-as-a-service for Global Pharmaceutical Companies.

​

Context:

The affordability challenge in healthcare is complex and evolving, characterized by both challenges and opportunities.

​

The Challenges

• Infrastructure gaps:
  Fragmented data infrastructure and facilities impossible to register and unify patient data

• Low credit coverage:
  More than 50% population are underbanked and struggle to get affordable financing

• Low insurance coverage:
  >40% costs are out-of-pocket even 90-100% for for essential and advanced treatment (cancer and rare diseases)
   

The Opportunities

• Technological advancements:
  Mobile health solutions offer new ways to collect data and register patient timely

• Innovation:
  Pharmaceutical companies are adopting digital solutions to accelerate growth in emerging regions, even financial aid to reach underserved patients through patient access programs

​

Market Size:

• Advanced drug sales for Oncology drug alone by 2028 (14% CAGR):
  SEA: $4B, APAC: $76B, Global: $1.4T

• Pharma companies currently spends billions for market access purposes in SEA
  Market access spending according to Economist Intelligence Unit database and BCG (2014): Vietnam ($3B), Thailand ($7.5B), Philippines ($5.7B), Indonesia ($9B), Singapore ($1.2B), Malaysia ($1.7B)

​

MedScore solution and product:

We solve the direct challenge of affordability with Fintech Credit Score:

identify and segmentize the underserved patients pool to receive aid from direct OEM (Pharmaceutical companies)
 

We enable all healthcare stakeholders (Pharmaceutical, Drug distributors, Hospital) to communicate, access and interact through Medscore Patient Data platform.

​

Core Advantages 

• Former Retail, Healthcare, and Education BNPL 
  (Vaccine pay later, C-section surgery pay later, Tuition pay later)

• Localized scoring tailored to specific market and patient behavior
  Expert in SEA lending and Consumer behavior PH, ID, TH, SG, and MY

• Localization technology for scale
  Geo location intelligence, scalable across geo boundaries

• Expert Management team with extensive SEA know-how
  Pharma Market Access, Fintech B2B2C, and Hospital management 

​

Case Studies:

Means Testing for Patient Access Program in SEA

Vietnam | Launched in Jan-2024

• Vietnam Ministry of Health approved the program on December 28, 2023.
  One of the largest PAP in Vietnam ever approved

• Drug: Oncology

• Scale: Tier 1 Public and Private hospitals across the country

• Patient scale: almost all provinces (62/63) in Vietnam

Philippines | Launching in Aug-2024​

• ​Drug: Oncology

• Scale: Tier 1 Public and Private across 03 main cities

Singapore | Bidding for launch in 2025 

• ​Drug: Rare diseases

• Scale: Confidential 

​

Curent Monetization (Phase 1) - B2B SaaS Model

• Annual Software Licensing 

• Underwriting Fee per Financial unit profile

Therapeutic focus: Cancer, Rare diseases

​

Future Monetization (Phase 2) - B2B2C Model

Revenue-sharing and patient acquisition initiatives beyond cancer

Therapeutic focus: Cancer, Rare diseases, Vaccine, Chronic diseases (Diabetics, Cardio)

​

Current Investors:

• Equity Investors: Ascend Vietnam Ventures, Son-Tech Investment, and Javis Ventures

• Grants approved (in Nov 2023) by Australian Development Investments (ADI)

• Venture Debt Facility with no Commitment Fee

​

Expert Team:

• CEO: Olivia - Product and Sales, 8+ years in Consumer Finance Product and Non-life Insurance (ex-GoBear, AIG). Harvard Medical School SEA Leadership in Medicine Class of 24/25

• Co-founders and C-level teams are Experts in Consumer Credit, Healthcare Management, and Market Access
  (ex-GoBear, Trusting Social, Property Guru, MSD)